ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2548

Assessment Of Worsening In Lupus Clinical Trials: Do The Endpoints Reflect Medical Judgement?

Aikaterini Thanou1, Eliza Chakravarty2, Stan Kamp3, Fredonna C. Carthen3 and Joan T. Merrill4, 1Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: BILAG

  • Tweet
  • Email
  • Print
Session Information

Session Title: Systemic Lupus Erythematosus-Clinical Aspects III: Biomarkers, Quality of Life and Disease Indicators, Late Complications

Session Type: Abstract Submissions (ACR)

Background/Purpose: Discrimination between treatment and placebo is problematic in lupus trials. Recently, composite endpoints have evolved which define response by both improvement in baseline findings and lack of clinically significant deterioration in other features. The predominant endpoints, the SLE Responder Index (SRI) and BILAG-Based Composite Lupus Assessment (BICLA), do not preclude the designation of response if there is one new moderate organ score (BILAG B) vs baseline but do exclude >/=2 new BILAG B scores. The British Isles Lupus Assessment Group (BILAG) has reported a provisional definition of flares (1). Here a moderate flare is defined as >/=2 B scores rated either new or worse. We addressed this disparity in defining a moderate, clinically significant deterioration in a cohort study.

Methods: The BILAG 2004 index was prospectively scored at the time of 182 clinic encounters of 91 patients.  Overall disease worsening was retrospectively judged by a clinician as either no worsening, mild, moderate, or severe flare.

Results:  

 

Physician-rated flares

 

No flare

Mild

Moderate

Severe

Total

 

BILAG  2004-defined flares (new or worse manifestations)

No new/worse A or B

103

9

0

0

112

 

1 B

1

20

16

2

39

 

>/=2 B (wo A)

0

2

11

3

16

 

        2 B

 

2

9

2

 

 

     >2 B

 

 

2

1

 

 

>/=1 A

2

0

5

8

15

 

       No B

2

3

5

 

       Plus  1B

2

1

 

       Plus  >/=2 B

2

 

Total

106

31

32

13

182

 

 

 

 

 

 

Physician-rated flares

 

No flare

Mild

Moderate

Severe

Total

 

BICLA and SRI-defined  Worsening (only new scores counted)

No new A or B

106

21

17

5

149

 

1 B

0

9

10

1

20

 

>/=2 B (wo A)

0

1

3

4

8

 

        2 B

 

1

2

3

 

 

     >2 B

 

 

1

1

 

 

>/=1 A

0

0

2

3

5

 

       No B

2

0

 

       Plus  1B

1

 

       Plus  >/=2 B

2

 

Total

106

31

32

13

182

 

Flares receiving one new BILAG B score or one new or worse B were usually considered mild by the clinician, confirming the approach by both constructs to discount increased disease at B level in only one organ as a moderate flare. Using the clinician’s judgement as a standard to distinguish moderate flares, the sensitivity of the BILAG cutoff of >/= 2 B “new or worse” (detecting all flares that were as severe or more severe than the cutoff) was 60.0% as opposed to 26.7% for the SRI/BICLA definition of >/= 2 “new” B scores. Specificities were 97.1% and 99.3% respectively.

Conclusion:   Whether worsening is defined by “new” or “new or worse” moderate disease, one BILAG B in isolation does not usually represent clinically significant deterioration by clinical judgement.  Limiting the definition of moderate deterioration to 2 “new” B scores, which is now common practice in clinical trials for lupus, is a very insensitive measure for the degree of clinical deterioration considered moderate (or worse) by a physician. The concept of moderate flare defined by the BILAG group (>/= 2 “new or worse” B scores) might be a more helpful approach to define a threshold of moderate, clinically significant deterioration in composite endpoints for SLE trials.

1. Isenberg DA, Allen E, Farewell V, et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Annals of the Rheumatic Diseases. 2011;70:54-59.


Disclosure:

A. Thanou,
None;

E. Chakravarty,
None;

S. Kamp,
None;

F. C. Carthen,
None;

J. T. Merrill,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-worsening-in-lupus-clinical-trials-do-the-endpoints-reflect-medical-judgement/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences